Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Increases By 36.2%

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 157,548 shares, an increase of 36.2% from the December 31st total of 115,672 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 596,577 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 596,577 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the stock are sold short.

Hedge Funds Weigh In On Inventiva

Large investors have recently bought and sold shares of the business. Creative Planning bought a new position in Inventiva in the 2nd quarter valued at $32,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after purchasing an additional 5,843 shares during the period. NewEdge Advisors LLC bought a new position in shares of Inventiva in the third quarter worth about $116,000. Millennium Management LLC purchased a new position in Inventiva in the 3rd quarter worth about $649,000. Finally, UBS Group AG lifted its holdings in Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

NASDAQ:IVA traded down $0.16 during mid-day trading on Friday, hitting $6.16. 519,422 shares of the stock traded hands, compared to its average volume of 614,614. Inventiva has a 52 week low of $2.23 and a 52 week high of $7.98. The firm’s 50 day moving average is $5.05 and its two-hundred day moving average is $4.81.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Inventiva to a “hold” rating in a report on Saturday, October 18th. Leerink Partners initiated coverage on Inventiva in a report on Monday, January 12th. They set an “outperform” rating and a $12.00 price objective on the stock. Wolfe Research upgraded Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. UBS Group initiated coverage on shares of Inventiva in a research note on Wednesday, January 7th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Guggenheim dropped their price objective on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $16.22.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.